Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.

Saved in:
Bibliographic Details
Title: Risk factors for CRS and ICANS with Bispecific Antibodies for Aggressive Lymphomas.
Authors: Gill VA; Brown University, Providence, Rhode Island, United States., Ollila TA; Brown University Health, Providence, Rhode Island, United States., Ghosh U; Brown University School of Public Health, Providence, Rhode Island, United States., Epperla N; Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States., Fitzgerald LA; University of Utah, Salt Lake CIty, Utah, United States., Grover NS; Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, North Carolina, United States., Stephens DM; University of North Carolina, Chapel Hill, North Carolina, United States., Thomas CJ; University of Pennsylvania, Philadelphia, Pennsylvania, United States., Tiger YKR; Mayo Clinic, Rochester, Minnesota, United States., Noveihed A; Rutgers University, New Brunswick, New Jersey, United States., Cortese MJ; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Herr MM; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Davis JA; Medical University of South Carolina, Charleston, South Carolina, United States., Hess BT; The Medical University of South Carolina, Charleston, South Carolina, United States., Kidwell A; University of Kansas Medical Center, Westwood, Kansas, United States., Shah NN; Medical College of Wisconsin, Wauwatosa, Wisconsin, United States., Moyo TK; Levine Cancer Institute, Atrium Helath, Charlotte, North Carolina, United States., Altomare N; Northwestern University, Chicago, Illinois, United States., Cohen JB; Emory University, Atlanta, Georgia, United States., Melody M; Tampa General Hospital Cancer Institute, Tampa, Florida, United States., Dharia A; USF Morsani College of Medicine, Brooksville, Florida, United States., Kenkre VP; University of Wisconsin, Madison, Wisconsin, United States., Shouse G; City of Hope, Duarte, California, United States., Moreira J; Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States., Ma S; Northwestern University, Chicago, Illinois, United States., Winter JN; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States., Gordon LI; Northwestern University, Feinberg School of Medicine, Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States., Karmali R; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States., Pelcovits A; Brown University/Brown University Health Cancer Institute, Providence, Rhode Island, United States.
Source: Blood advances [Blood Adv] 2026 Sep 24. Date of Electronic Publication: 2026 Sep 24.
Publication Type: Journal Article
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2026020595